Association of plasma homovanillic acid with behavioral symptoms in patients diagnosed with dementia: a preliminary report.
Neuroleptic treatment of psychotic symptoms or agitated behavior in elderly patients diagnosed with dementia is associated with reduced efficacy and increased rates of neuroleptic-induced parkinsonism in comparison to younger patients with schizophrenia. We report the first study to examine the relationship between an in vivo measure of dopaminergic function, plasma homovanillic acid (pHVA), and ratings of psychosis, agitation, and parkinsonism before and after neuroleptic treatment in dementia patients. Pretreatment pHVA was significantly correlated with parkinsonian rigidity, with a trend observed with agitation and hostility. Though mean pHVA did not change during perphenazine treatment, intraindividual change in pHVA at day 15 was correlated with improvement in hostility, with a similar trend for improvement in agitation. These preliminary findings are consistent with reports associating dopaminergic function with agitated, but not psychotic, symptoms in patients diagnosed with dementia, and with a reduced responsivity of dopaminergic systems to neuroleptic treatment in these patients.
Sweet
R A
RA
University of Pittsburgh School of Medicine, Pennsylvania, USA.
Pollock
B G
BG
Mulsant
B H
BH
Rosen
J
J
Lo
K H
KH
Yao
J K
JK
Henteleff
R A
RA
Mazumdar
S
S
D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000097:blood* / Q000188:drug therapy / Q000523:psychology*; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001519:Behavior / Q000187:drug effects; D004409:Dyskinesia, Drug-Induced / Q000097:blood; D005260:Female; D006719:Homovanillic Acid / Q000097:blood*; D006801:Humans; D008297:Male; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000523:psychology; D010546:Perphenazine / Q000009:adverse effects / Q000627:therapeutic use
D014150:Antipsychotic Agents; D010546:Perphenazine; D006719:Homovanillic Acid